Results 271 to 280 of about 1,191,068 (306)
Some of the next articles are maybe not open access.
American Journal of Obstetrics and Gynecology, 1984
CA 125 and CA 19-9 are antigenic determinants associated with human epithelial ovarian carcinomas. Murine monoclonal antibodies have been raised against these determinants, and immunoradiometric assays have been developed to monitor antigen levels in the serum of cancer patients. This study was undertaken to determine whether concomitant measurement of
R C, Bast +7 more
openaire +2 more sources
CA 125 and CA 19-9 are antigenic determinants associated with human epithelial ovarian carcinomas. Murine monoclonal antibodies have been raised against these determinants, and immunoradiometric assays have been developed to monitor antigen levels in the serum of cancer patients. This study was undertaken to determine whether concomitant measurement of
R C, Bast +7 more
openaire +2 more sources
Elevated Tumor-Associated Antigen CA 19-9 in a Patient With an Enlarged Pancreas
Southern Medical Journal, 1997Carbohydrate antigen 19-9 (CA 19-9) has been used as a serum tumor marker for adenocarcinoma of the upper gastrointestinal tract, particularly primary adenocarcinoma of the pancreas. This tumor marker has also been used to differentiate benign from malignant diseases of the pancreas.
B A, Tolliver, B L, O'Brien
openaire +2 more sources
The clinical utility of the CA 19-9 tumor-associated antigen.
The American journal of gastroenterology, 1990Since Koprowski and coworkers discovered the CA 19-9 antigen 10 yr ago, it has become the most useful blood test in the diagnosis and management of patients with cancer of the pancreas. With an upper limit of normal of 37 U/ml, the assay's overall sensitivity is approximately 80% and its specificity is 90%.
openaire +1 more source
[Assay of serum carbohydrate antigen (CA) 19-9 in the diagnosis of gastric cancer].
Gan to kagaku ryoho. Cancer & chemotherapy, 1986The levels of the serum carbohydrate antigen (CA) 19-9 were assayed in 284 cases including 77 patients with gastric cancer. The CA 19-9 levels were positive in 38% of gastric cancer cases, and they were significantly higher than those of benign gastric diseases.
K, Nishida +7 more
openaire +1 more source
Vestnik Rossiiskoi akademii meditsinskikh nauk, 1993
Enzyme immunoassay was used to study blood levels of CA-19-9, cancerous embryonal antigen, and alpha-fetoprotein in blood donors (n = 33), patients with chronic pancreatitis (n = 35), those with pancreatic carcinoma with metastases (n = 28), and without them (n = 21).
S V, Skvortsov +2 more
openaire +1 more source
Enzyme immunoassay was used to study blood levels of CA-19-9, cancerous embryonal antigen, and alpha-fetoprotein in blood donors (n = 33), patients with chronic pancreatitis (n = 35), those with pancreatic carcinoma with metastases (n = 28), and without them (n = 21).
S V, Skvortsov +2 more
openaire +1 more source
[Antigens (CEA and CA 19-9) in diagnosis and prognosis colorectal cancer].
Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2002carcinoembryonic antigen (CEA) was first described more than three decades ago, when its presence was demonstrated in fetal gut tissue and in tumors from gastrointestinal tract. Subsequently, CEA was detected in the circulation of patients and recognized as a serum marker for colorectal cancer.
openaire +1 more source
Acta bio-medica de L'Ateneo parmense : organo della Societa di medicina e scienze naturali di Parma, 1986
CA 19-9, a new antigenic tumor marker for gastrointestinal tumors, has been assayed with Carcinoembriogenic antigen, in 90 healthy patients and 47 patients with gastric cancer (20) and colorectal cancer (27). A good specificity has been found for this antigen (97.7%). Its sensibility seems to be slightly superior to that of CEA. However the sensibility
E, Capocasale +4 more
openaire +1 more source
CA 19-9, a new antigenic tumor marker for gastrointestinal tumors, has been assayed with Carcinoembriogenic antigen, in 90 healthy patients and 47 patients with gastric cancer (20) and colorectal cancer (27). A good specificity has been found for this antigen (97.7%). Its sensibility seems to be slightly superior to that of CEA. However the sensibility
E, Capocasale +4 more
openaire +1 more source
Critical care management of chimeric antigen receptor T‐cell therapy recipients
Ca-A Cancer Journal for Clinicians, 2022Alexander Shimabukuro-Vornhagen +2 more
exaly
CA 19-9 and Lewis Antigens in Pancreatic Cancer
Journal of Clinical Oncology, 2009openaire +2 more sources